DGP-Kongress 2024 – „Key Takeaways aus Keynote Lectures“: Pneumologie erblühe: selbstbewusst, zukunftsorientiert und präventiv orientiert

• Literatur

• 1 Behr J, Prasse A, Kreuter M. et al.; RELIEF investigators. Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial. Lancet Respir Med 2021; 9: 476-486
• 2 Walmrath D, Schneider T, Pilch J. et al. Aerosolised prostacyclin in adult respiratory distress syndrome. Lancet 1993; 342 (8877): 961-962
• 3 Pullamsetti SS, Kojonazarov B, Storn S. et al. Lung cancer-associated pulmonary hypertension: Role of microenvironmental inflammation based on tumor cell-immune cell cross-talk. Sci Transl Med 2017; 9(416): eaai9048
• 4 Eul B, Cekay M, Pullamsetti SS. et al. Noninvasive Surrogate Markers of Pulmonary Hypertension Are Associated with Poor Survival in Patients with Lung Cancer. Am J Respir Crit Care Med 2021; 203 (10): 1316-1319
• 5 Pullamsetti SS, Savai R, Seeger W. et al. Translational Advances in the Field of Pulmonary Hypertension. From Cancer Biology to New Pulmonary Arterial Hypertension Therapeutics. Targeting Cell Growth and Proliferation Signaling Hubs. Am J Respir Crit Care Med 2017; 195 (4): 425-437
• 6 Seimetz M, Parajuli N, Pichl A. et al. Inducible NOS inhibition reverses tobacco-smoke-induced emphysema and pulmonary hypertension in mice. Cell 2011; 147 (2): 293-305
• 7 Seimetz M, Sommer N, Bednorz M. et al. NADPH oxidase subunit NOXO1 is a target for emphysema treatment in COPD. Nat Metab 2020; 2 (6): 532-546
• 8 WHO Tobacco Use Trends Report 2024. https://www.who.int/publications/i/item/9789240088283